SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-003665
Filing Date
2022-03-15
Accepted
2022-03-15 08:29:45
Documents
13
Period of Report
2022-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20220315.htm   iXBRL 8-K 52900
2 EX-99.1 ovid-ex99_1.htm EX-99.1 153135
  Complete submission text file 0000950170-22-003665.txt   345858

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20220315.xsd EX-101.SCH 2494
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20220315_pre.xml EX-101.PRE 11578
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20220315_lab.xml EX-101.LAB 17811
7 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20220315_htm.xml XML 4882
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 22739213
SIC: 2834 Pharmaceutical Preparations